108 related articles for article (PubMed ID: 26263187)
1. Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis.
Chung SW; Lee BS; Choi Ju; Kim SW; Kim IS; Kim SY; Byun Y
J Med Chem; 2015 Aug; 58(16):6435-47. PubMed ID: 26263187
[TBL] [Abstract][Full Text] [Related]
2. Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy.
Lee BS; Cho YW; Kim GC; Lee DH; Kim CJ; Kil HS; Chi DY; Byun Y; Yuk SH; Kim K; Kim IS; Kwon IC; Kim SY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505252
[TBL] [Abstract][Full Text] [Related]
3. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
[TBL] [Abstract][Full Text] [Related]
5. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
6. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
[TBL] [Abstract][Full Text] [Related]
8. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug.
Cho YS; Chung SW; Kim HR; Won TH; Choi JU; Kim IS; Kim SY; Byun Y
J Control Release; 2019 Feb; 296():241-249. PubMed ID: 30659905
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
[TBL] [Abstract][Full Text] [Related]
10. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
11. Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.
Asakura T; Sawai T; Hashidume Y; Ohkawa Y; Yokoyama S; Ohkawa K
Br J Cancer; 1999 May; 80(5-6):711-5. PubMed ID: 10360648
[TBL] [Abstract][Full Text] [Related]
12. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
13. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.
Chung SW; Choi JU; Lee BS; Byun J; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Biomaterials; 2016 Jul; 94():1-8. PubMed ID: 27085176
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa C; Mann-Steinberg H; Fichtner I; Weber H; Satchi-Fainaro R; Biniossek ML; Kratz F
Bioconjug Chem; 2008 Jul; 19(7):1414-22. PubMed ID: 18578486
[TBL] [Abstract][Full Text] [Related]
15. Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic-DEVD-Doxorubicin Conjugate for Targeted Cancer Therapy.
Yang SB; Lee DN; Lee JH; Seo M; Shin DW; Lee S; Lee YH; Park J
Bioconjug Chem; 2023 Feb; 34(2):333-344. PubMed ID: 36735902
[TBL] [Abstract][Full Text] [Related]
16. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
17. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.
Fernandez AM; Van Derpoorten K; Dasnois L; Lebtahi K; Dubois V; Lobl TJ; Gangwar S; Oliyai C; Lewis ER; Shochat D; Trouet A
J Med Chem; 2001 Oct; 44(22):3750-3. PubMed ID: 11606140
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.
Santra S; Kaittanis C; Santiesteban OJ; Perez JM
J Am Chem Soc; 2011 Oct; 133(41):16680-8. PubMed ID: 21910482
[TBL] [Abstract][Full Text] [Related]
19. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
20. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
